Post Reply
21-28 of 28
No. 60cts no sale
Proposed privatisation of TalkMed Group Limited @ $0.456
&bull Privatisation will be effected by way of a scheme of arrangement
&bull Transaction to result in a combined entity that enhances patient care, by providing access to a wider
range of services and expertise and by creating opportunities for oncologists to sub-specialise
&bull Opportunity for shareholders to realise investment at a premium
&bull Significant opportunities for value creation, leveraging Tamarind Health&rsquo s regional platform
TalkMed says acquisition discussions are &lsquo ongoing&rsquo in fifth update
Tertiary healthcare service provider TalkMed Group says acquisitions discussions are &ldquo ongoing&rdquo in an update, according to a Sept 19 bourse filing.
This is the fifth update since the company&rsquo s board of directors first announced that it had received indications of &ldquo interests from persons who are considering acquisition of a stake in the company&rdquo .
The company&rsquo s board of directors add that &ldquo there is no assurance that a transaction will take place&rdquo .
Future announcements are expected to follow subject to material developments, says the board of directors.
On July 15, the company reported earnings of $8.6 million in 1HFY2024 ended June 30, down 31.1% y-o-y in 1HFY2023. Revenue in the same period was down 12.4% y-o-y at $33.1 million.
TalkMed was listed in 2014, with its IPO shares priced at 20 cents each. Its shares surged to an all-time high of 89 cents in 2017.
TalkMed says acquisition discussions remain &lsquo preliminary&rsquo in third update
Medical oncology and stem cell services provider TalkMed Group, which announced in April &ldquo interest&rdquo from &ldquo persons&rdquo considering the acquisition of a stake in the company, says the discussions remain &ldquo preliminary&rdquo .
&ldquo There is no assurance that a transaction will take place,&rdquo reads a July 22 bourse filing.
This is the third update since its board of directors announced on April 6 that it had &ldquo received indication of interest from persons who are considering acquisition of a stake in the company&rdquo .
&ldquo Accordingly, shareholders are advised to refrain from taking any action in respect of their shares in the company, which may be prejudicial to their interests, and to exercise caution when dealing in the shares,&rdquo says its board of directors. &ldquo The company will, in compliance with its disclosure obligations under the SGX-ST Listing Rules, update shareholders in due course when it becomes aware of any material developments.&rdquo
TalkMed, a specialist cancer medical group, is controlled by group CEO Dr Ang Peng Tiam, who has an interest in 64.74% of the shares via Ladyhill Holdings. Group COO Dr Khoo Kei Siong holds another 7.49%.
On Feb 20, the company reported earnings of $32.7 million for FY2023, up 9.7% over the preceding year ended Dec 31, 2022. Revenue in the same period was up 9.4% to $83.8 million, due to higher patient numbers.
Despite the better earnings, Talkmed is paying a lower dividend of 1.3 cents for FY2023, down from 1.5 cents paid for FY2022.
TalkMed was listed back in 2014, with its IPO shares offered at 20 cents each. Its shares surged to an all-time high of 89 cents in 2017.
No supporting figures to support your belief. Below simple FA figures tells the truth unless proven otherwise.
hotelgrand ( Date: 23-Feb-2018 11:39) Posted:
|
If that is true overpriced must as well short this stock till its ipo price of 25cts..When ipo it went over 60cts and about a few months later stablished from 90cts to $1.10.
Subsequently 1-2 years later 1 forv1 bonus this stock shot up from $1.15 to reach a peak of $1.80 before ex bonus.Kenna controlled so difficult to come down.fyi my opinion only.
Wonder why open a new thread just to claim this counter is overpriced.Mr Market is smart and efficient so stock cheap or expensive will adjust itself unless yourself interest hoping to talk the counter to drop..haha
Ya, thats because Dr Ang Peng Tiam of TalkMed had treated PM LHL for cancer. So he became very famous. This is all about his Brand. Other than that, nothing really special I think.
As compare with Singapore O& G, it seems that TalkMed is over price or expensive.
TalkMed PE 27.87 based on 68 while Singapore O& G PE 21.63 based on 38.5
TalkMed yield 3.13% while Singapore O& G yield 3.9%
TalkMed P/BV 12.36 time while Singapore O& G 4.22 time